A first-in-class treatment
The U.S. Food and Drug Administration approved Oveporexton, sold under the brand name Orzeyful, on August 5. The tablet is for adults with narcolepsy type 1, a lifelong neurological disorder. It is the first orexin receptor 2 agonist to reach the U.S. market and the first medicine approved to treat the full range of narcolepsy type 1 symptoms.
Narcolepsy type 1 is caused by the loss of orexin, a brain chemical that helps control wakefulness and sleep. Older drugs manage individual symptoms such as excessive daytime sleepiness or cataplexy — sudden muscle weakness — but do not address the cause. Oveporexton restores orexin signaling directly.
What the trials showed
The approval rests on two global Phase 3 trials called FirstLight and RadiantLight. Both enrolled adults with narcolepsy type 1. The studies showed statistically meaningful improvements in excessive daytime sleepiness, cataplexy frequency and health-related quality of life, according to Takeda.
The FDA granted the drug Priority Review and Breakthrough Therapy designation, reflecting the unmet need in this patient group. The agency accepted Takeda's application in February 2026.
What it means for patients
“For too long, people with narcolepsy type 1 have had to manage a complex, lifelong neuropsychiatric condition with treatments that only address pieces of it,” said Tiffany R. Farchione, director of the Division of Psychiatry at the FDA's Center for Drug Evaluation and Research. “This new drug is the first medicine that impacts the underlying biology of the disease, treating narcolepsy type 1 as a whole.”
Takeda plans to bring the drug to adults with narcolepsy type 1 as quickly as possible. Julie Kim, the company's president and chief executive, called the approval “a new chapter” for the narcolepsy type 1 community and said the new class of medicine could redefine how the disease is managed.